PYXS Stock Analysis: Buy, Sell, or Hold?
PYXS - Pyxis Oncology, Inc. Common Stock
$2.02
-0.26 (-11.40%)
▼
5d:
-26.55%
30d:
+21.69%
90d:
+51.88%
WAIT
LOW Confidence
Analysis Updated: May 18, 2026 12:00 AM ET
Earnings: May 21, 2026
1d
Get Alerted When PYXS Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: PYXS is down 26.5% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: PYXS is down 26.5% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: PYXS is currently trading at $2.02, which is considered slightly high relative to its 30-day fair value range of $1.51 to $2.26.
Technical Outlook: Technically, PYXS is in a uptrend. Immediate support is located at $1.71, while resistance sits at $2.92. Short-term momentum is weak, with the stock down 11.4% recently.
Market Sentiment: The stock shows a mixed technical setup (55/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $6.78 (+235.5%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, PYXS is in a uptrend. Immediate support is located at $1.71, while resistance sits at $2.92. Short-term momentum is weak, with the stock down 11.4% recently.
Market Sentiment: The stock shows a mixed technical setup (55/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $6.78 (+235.5%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
SLIGHTLY HIGH
Historical Trading Range
$1.51 -
$2.26
Company Quality Score
59/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
61.6%
All Signals
- NEUTRAL: Mixed technical signals (55/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-11.4%)
- BULLISH: Trading 235.5% below Wall St target ($6.78)
- WARNING: Recommendation downgraded due to -26.5% 5-day decline - wait for stabilization
Trading Range Analysis
30-Day Trading Range
$1.51 -
$2.26
Current vs Trading Range
SLIGHTLY HIGH
Support & Resistance Levels
Support Level
$1.71
Resistance Level
$2.92
Current Trend
Uptrend
Technical data as of
May 18, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-1.64
Wall Street Target
$6.78
(+235.5%)
Share & Embed Analysis
Last updated: May 19, 2026 3:27 AM ET
Data refreshes hourly during market hours. Next update: 4:27 AM
Data refreshes hourly during market hours. Next update: 4:27 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is PYXS showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ALNY
Alnylam Pharmaceuticals … |
STRONG BUY
33 analysts |
$449 | 56 HOLD |
|
SRPT
Sarepta Therapeutics Inc |
STRONG BUY
26 analysts |
$22 | 51 HOLD |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$35 | 56 HOLD |
|
INSM
Insmed Inc |
STRONG BUY
19 analysts |
$203 | 53 HOLD |
|
VRDN
Viridian Therapeutics Inc |
STRONG BUY
16 analysts |
$34 | 58 HOLD |
